Creative Medical Technology
CELZ
14 hedge funds and large institutions have $735K invested in Creative Medical Technology in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
75% more funds holding
Funds holding: 8 → 14 (+6)
67% more capital invested
Capital invested by funds: $441K → $735K (+$294K)
0.3% more ownership
Funds ownership: 0% → 0.3% (+0.3%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
+$69.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56K |
| 3 |
State Street
Boston,
Massachusetts
|
+$51.1K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$48.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$38.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$177K |
| 2 |
Jane Street
New York
|
-$137K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$50K |
| 4 |
LCS
Levin Capital Strategies
New York
|
-$22K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$67 |
CELZ Hedge Fund Activity: Q1 2022 in Review
14 of the 6,359 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q1 2022, worth a combined $735K — up 67% from $441K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CELZ positions and 5 closed out — a net gain of 6 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sassicaia Capital Advisers, opening a new position worth an estimated $69.4K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $177K sold.
- 14 institutional investors held Creative Medical Technology (CELZ) as of Q1 2022, up from 8 in Q4 2021.
- Funds reported $735K of Creative Medical Technology stock for Q1 2022, up 67% quarter-over-quarter.
- 11 funds opened new Creative Medical Technology positions in Q1 2022 and 5 closed out, a net change of +6 holders.
- The largest Creative Medical Technology buyer in Q1 2022 was Sassicaia Capital Advisers, an estimated $69.4K added.
- The largest Creative Medical Technology seller in Q1 2022 was Hudson Bay Capital Management, an estimated $177K sold.
Based on aggregated 13F filings for Q1 2022.